European Medicines Agency relocation - Competition Lawyer comments
19 cities are battling it out today to host the European Medicines Agency when it relocates from Canary Wharf. Commenting on this, Mishcon de Reya Competition Lawyer Natasha Pearman said:
"Even after all the intense lobbying over the last few months, the decision could still come down to a drawing of lots if there is no clear winner after voting. Bookmakers have Milan in the lead as 2/1 favourite, followed by Bratislava at 5/1. However, recent staff surveys of the European Medicines Agency (EMA) show that a move to Bratislava would create serious disruption to the approval of medicines, with less than 30% of employees saying they would relocate to Slovakia.
"This could give the UK some leverage in Brexit negotiations in that the Medicines and Healthcare products Regulatory Agency (MHRA) could – and should – position itself in such a way as to plug any gaps created by such a move.
"The commercial implications for the medical industry could be significant: it will take the EMA some time to get back up and running, and is likely to result in a marked slowdown of the approval of new medicines. Clearly the EMA needs to continue to operate effectively and without jeopardising patient safety."
To arrange an interview, please contact email@example.com / 020 7637 0656